Anti-infectives: New oral HCV drug shows promise

Man Tsuey Tse
July 2010
Nature Reviews Microbiology;Jul2010, Vol. 8 Issue 7, p464
Academic Journal
The article reports on a study which demonstrated the potent antiviral effects of BMS-790052, a new first-in-class compound for hepatitis C virus (HCV) infection. The drug was evaluated in a Phase I clinical trial of patients chronically infected with HCV. The results suggest that the agent could lead to therapeutic regimens with better tolerability and improved clinical outcomes.


Related Articles

  • New treatments for genotype I chronic hepatitis C - focus on simeprevir. Kanda, Tatsuo; Nakamoto, Shingo; Wu, Shuang; Yokosuka, Osamu // Therapeutics & Clinical Risk Management;2014, Vol. 10, p387 

    Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepatocellular carcinoma. In the USA, Canada, and Japan, simeprevir - one of the second -generation HCV NS3/4A protease inhibitors - in combination with peginterferon а-2a or 2b plus ribavirin has recently been...

  • Study identifies when to re-treat hepatitis C and in which patients. Mayor, Susan // British Journal of Hospital Medicine (17508460);Jun2008, Vol. 69 Issue 6, p319 

    The article reports on the international REPEAT randomized clinical trial involving 942 patients with detectable levels of hepatitis C (HCV) RNA after 12 weeks of treatment with peginterferon alfa-2b and ribavirin. It was observed that patients who show a substantial decrease in HCV RNA have the...

  • Chronic hepatitis C: 'interferon-like' therapy increases response rates. Dawber, Steve // British Journal of Hospital Medicine (17508460);Jun2008, Vol. 69 Issue 6, p319 

    The article reports on a 48-week STEALTH-C randomized clinical trial involving treatment-naive patients with chronic hepatitis C. Results indicated that compared to the usual care, the interferon-like, intracellular signaling enhancer nitazoxanide can enhance sustained virological response rates...

  • Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials. Chary, Aarthi; Holodniy, Mark // Reviews on Recent Clinical Trials;Sep2010, Vol. 5 Issue 3, p158 

    Hepatitis C virus (HCV) infection affects millions of people world-wide, and chronic infection can result in end-stage liver disease and hepatocellular carcinoma. Conventional therapy to date has involved combination antiviral therapy including alpha-interferon and ribavirin; response rates with...

  • Hepatitis C in the interferon-free era. Streinu-Cercel, Adrian // Germs;Dec2013, Vol. 3 Issue 4, p114 

    The editor discusses the in-depth study of the genetic structure of hepatitis C virus (HCV) which described the viral life cycle and the ideal targets for direct-acting antivirals (DAAs). Topics discussed include enzymatic targets for antivirals attacks, viral proteins role in establishing...

  • How INFORM-1 May Change HCV Drug Development. Morrison, Trista // BioWorld Financial Watch;5/4/2009, Vol. 17 Issue 18, p1 

    The article discusses preliminary data on INFORM-1, the first study to combine two direct-acting antivirals for hepatitis C, which was presented at the 44th annual meeting of the European Association for the Study of the Liver (EASL). The encouraging outcomes of the trial are identified, such as...

  • EASL Roundup.  // BioWorld Today;4/27/2009, Vol. 20 Issue 79, p3 

    The article reports on the positive results from a Phase 1b single-agent study of oral antiviral drug, candidate, SCY-365, a cyclophilin inhibitor from Scynexis Inc. in adult patients with genotype 1 chronic hepatitis C virus (HCV). SCY-635 was said to be well tolerated with no serious adverse...

  • Prospects for Prophylactic and Therapeutic Vaccines Against Hepatitis C Virus. Feinstone, Stephen M.; Hu, Dale J.; Major, Marian E. // Clinical Infectious Diseases;Jul2012 Supplement 1, Vol. 55 Issue suppl_1, pS25 

    Natural cross-protective immunity is induced after spontaneous clearance of primary hepatitis C virus (HCV) infection. Although this suggests that effective prophylactic vaccines against HCV are possible, there are still several areas that require further study. Current data indicate that, at...

  • Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Feng, Bo; Eknoyan, Garabed; Guo, Zhong-sheng; Jadoul, Michel; Rao, Hui-ying; Zhang, Wei; Wei, Lai // Nephrology Dialysis Transplantation;Jan2012, Vol. 27 Issue 2, p640 

    Background. Hepatitis C virus (HCV) is associated with various glomerulopathies, in which HCV is responsible not only for the onset of glomerulopathy but also for its progressive loss of kidney function. The effect of antiviral treatment on the glomerular lesions and subsequent course of kidney...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics